Teclistamab Outperforms Len/Dex in High-Risk Smoldering Myeloma With Higher CR Rate, PFS: Omar Nadeem, MD

Why It Matters

The results suggest that early BCMA‑directed therapy can deliver curative‑level responses, potentially redefining the standard of care for high‑risk smoldering myeloma and reducing progression to overt disease.

Key Takeaways

• Teclistamab achieved 73% CR versus 0% with Len/Dex.
• 2‑year PFS estimated at 92% for teclistamab.
• MRD negativity reached 81% with teclistamab, none with control.
• No grade ≥3 cytokine release syndrome observed.
• Trial enrolled 59 high‑risk smoldering myeloma patients.

Pulse Analysis

The management of high‑risk smoldering multiple myeloma has long been a therapeutic gray zone. Although the disease is asymptomatic, roughly half of patients progress to overt myeloma within two years, prompting clinicians to seek pre‑emptive strategies. The 2025 FDA approval of daratumumab‑hyaluronidase (Darzalex Faspro) marked the first disease‑modifying option, delivering response rates near 60 % but leaving a sizable proportion of patients without deep remission. Consequently, the hematology community has been watching for agents that can deliver higher complete‑response rates while preserving quality of life.

The phase 2 ImmunoPRISM trial provides that missing piece. In a randomized 2:1 design, teclistamab—a BCMA‑directed bispecific antibody—produced a 73 % complete‑response rate compared with zero in the lenalidomide‑dexamethasone arm, and 86.7 % of patients achieved VGPR or better. Equally striking, MRD negativity at 10⁻⁵ reached 81 % versus none, translating into an estimated two‑year progression‑free survival of 92 % versus 51 %. These efficacy signals surpass the outcomes seen with daratumumab‑Faspro, suggesting that earlier BCMA targeting can eradicate residual clones before they evolve resistance.

Safety data reinforce teclistamab’s appeal; the study reported no high‑grade cytokine release syndrome and comparable infection rates to standard therapy, a notable improvement over the toxicity profile observed in relapsed‑refractory settings. If these findings hold in larger phase 3 cohorts, regulators may consider expanding the label to include high‑risk smoldering disease, reshaping treatment algorithms that currently rely on watchful waiting or lenalidomide‑based regimens. Payers will likely evaluate cost‑effectiveness given the drug’s premium pricing, but the potential to prevent full‑blown myeloma could offset long‑term expenditures. Ultimately, teclistamab could become the new benchmark for early‑line intervention in a population poised for rapid disease evolution.